FDA Grants Fast Track Designation to CAR T-cell Therapy for Mesothelioma
The U.S. Food and Drug Administration (FDA) issued a fast track designation to a CAR T-cell therapy for malignant mesothelioma.
The FDA granted this designation to the CAR T-cell therapy SynKIR-110. This treatment helps a mesothelioma patient’s T-cells more effectively target mesothelioma cells. SynKIR-110 programs the T-cells to look for the protein mesothelin, which is often expressed on the surface of mesothelioma cells.
SynKIR-110 is developed by Verismo Therapeutics, which is a biopharmaceutical spinout from Penn Medicine at the University of Pennsylvania. Penn Medicine’s Abramson Cancer Center is one of the top mesothelioma cancer centers.
SynKIR-110 will be featured in a phase 1 clinical trial for patients with mesothelin-expressing mesothelioma, cholangiocarcinoma and ovarian cancer. The trial is expected to enroll patients starting in the first half of 2023. It’s a first-in-human clinical trial of the CAR T-cell therapy, which uses a dual-chain platform to target mesothelin and DAP12 to improve T-cell stimulation.
https://www.mesotheliomaguide.com/community/car-t-cell-therapy-for-mesothelioma-fda-fast-track/
ارسال به دوستان